

Clinical Policy: Cosyntropin (Cortrosyn)

Reference Number: CP.PHAR.203

Effective Date: 04.01.16

Last Review Date: 02.18

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Cortrosyn (Cortrosyn[®]) is a synthetic subunit of adrenocorticotrophic hormone.

FDA Approved Indication(s)

Cortrosyn is indicated for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Policy/Criteria

Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria

It is the policy of health plans affiliated with Centene Corporation[®] that Cortrosyn is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Presumed Adrenocortical Insufficiency (must meet all):

1. Prescribed for diagnostic testing of adrenocortical insufficiency;
2. Dose does not exceed one of the following (a or b):
 - a. If age \leq 2 years: 0.25 mg/dose (1 vial);
 - b. If age $>$ 2 years: 0.75 mg/dose (3 vials).

Approval duration: 1 dose

B. Other diagnoses/indications

1. Refer to CP.PMN.53 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Presumed Adrenocortical Insufficiency (must meet all):

1. Continuation of therapy will not be granted. Member must meet the initial approval criteria.

Approval duration: N/A

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 3 months (whichever is less); or

CLINICAL POLICY

Cosyntropin

2. Refer to CP.PMN.53 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.PMN.53 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

Not applicable

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
For diagnosis of adrenal insufficiency	0.25-0.75 mg IV or IM; in pediatric patients ≤ 2 years, 0.125 mg will often suffice	0.75 mg/dose

VI. Product Availability

Vial for injection: 0.25 mg

VII. References

1. Cosyntropin Prescribing Information. Rockford, IL : Mylan Institutional, LLC; January 2013. Available at <http://www.mylan.com/en/products/product-catalog/product-profile-page?id=CF5A292-052C-4646-A4FA-84904388960D>. Accessed October 30, 2017.
2. Cortrosyn Prescribing Information. Rancho Cucamonga, CA. Amphastar Pharmaceuticals, Inc.; September 2010. Available at <http://www.cortrosyn.com>. Accessed October 30, 2017.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J0833	Injection, cosyntropin, not otherwise specified, 0.25 mg
J0834	Injection, cosyntropin (Cortrosyn), 0.25 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy developed.	03.16	04.16
Removed requirement related to contraindications to cosyntropin (i.e., no hypersensitivity to any component,	03.17	04.17

CLINICAL POLICY
Cosyntropin

Reviews, Revisions, and Approvals	Date	P&T Approval Date
no allergic reaction or anaphylaxis to cosyntropin) from initial approval section. Added continuation criteria to clarify that continuation of therapy will not be granted and member must meet the initial approval criteria.		
1Q18 annual review: - Modified max dose criteria from 0.125 mg to 0.25 mg for age \leq 2 years since 0.125 is not a true max per labeling, plus partial vials cannot be dispensed so a dose of 0.125 is unenforceable post-approval. - References reviewed and updated.	10.30.17	02.18

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise

CLINICAL POLICY**Cosyntropin**

professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.